Impact of Chronic Kidney Disease on Platelet Function Profiles in Diabetes Mellitus Patients With Coronary Artery Disease Taking Dual Antiplatelet Therapy

Journal of the American College of Cardiology

Volumn 55, Issue 11, 2010, Pages 1139-1146

  Angiolillo, Dominick J ^a   Bernardo, Esther ^b   Capodanno, Davide ^a   Vivas, David ^b   Sabaté, Manel ^b   Ferreiro, José Luis ^a   Ueno, Masafumi ^a   Jimenez Quevedo, Pilar ^b   Alfonso, Fernando ^b   Bass, Theodore A ^a   Macaya, Carlos ^b   Fernandez Ortiz, Antonio ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

chronic kidney disease; clopidogrel; diabetes mellitus; platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; COLLAGEN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR; INSULIN; NITRIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT; PADGEM PROTEIN; PROTON PUMP INHIBITOR;

ADJUVANT THERAPY; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CELL ASSAY; CELL STIMULATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DOSE KIDNEY FUNCTION RELATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KIDNEY DYSFUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

AGED; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 77649207350     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.10.043     Document Type: Article

References (49)

1. Mann J.F., Gerstein H.C., and Pogue J. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134 (2001) 629-636
2. Muntner P., He J., and Hamm L. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13 (2002) 745-753
3. Coresh J., Astor B.C., Greene T., Eknoyan G., and Levey A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 (2003) 1-12
4. Hage F.G., Venkataraman R., Zoghbi G., Perry G.J., DeMattos A.M., and Iskandrian A.E. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 53 (2009) 2129-2140
5. Gruberg L., Dangas G., and Mehran R. Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure. Catheter Cardiovasc Interv 55 (2002) 66-72
6. Best P.J., Lennon R., Ting H.H., et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol (2002) 1113-1119
7. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
8. de la Torre-Hernández J.M., Alfonso F., Hernández F., et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 51 (2008) 986-990
9. Lambert N.D., Sacrinty M.T., Ketch T.R., et al. Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction. Am Heart J 157 (2009) 688-694
10. Zhu Z.B., Zhang R.Y., Zhang Q., et al. Moderate-severe renal insufficiency is a risk factor for sirolimus-eluting stent thrombosis. The RIFT study. Cardiology 112 (2009) 191-199
11. Aoki J., Lansky A.J., Mehran R., et al. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 119 (2009) 687-698
12. Latif F., Kleiman N.S., Cohen D.J., Pencina M.J., et al. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. J Am Coll Cardiol Intv 2 (2009) 37-45
13. Kuchulakanti P.K., Chu W.W., Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
14. Machecourt J., Danchin N., Lablanche J.M., et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 50 (2007) 501-508
15. Best P.J., Steinhubl S.R., Berger P.B., et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 155 (2008) 687-693
16. Dasgupta A., Steinhubl S.R., Bhatt D.L., et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] trial). Am J Cardiol 103 (2009) 1359-1363
17. Brancati F.L., Whelton P.K., Randall B.L., Neaton J.D., Stamler J., and Klag M.J. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT: Multiple Risk Factor Intervention Trial. JAMA 278 (1997) 2069-2074
18. Fox C.S., Larson M.G., Leip E.P., Culleton B., Wilson P.W., and Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA 291 (2004) 844-850
19. Fox C.S., Larson M.G., Leip E.P., Meigs J.B., Wilson P.W., and Levy D. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care 28 (2005) 2436-2440
20. U.S. Renal Data System, USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States (2006), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
21. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54 (2005) 2430-2435
22. Angiolillo D.J., Bernardo E., Ramírez C., et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48 (2006) 298-304
23. Angiolillo D.J., Shoemaker S.B., Desai B., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115 (2007) 708-716
24. Geisler T., Anders N., Paterok M., et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 30 (2007) 372-374
25. Natarajan A., Marshall S.M., Worthley S.G., Badimon J.J., and Zaman A.G. The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus. J Thromb Haemost 6 (2008) 2210-2213
26. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
27. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management and future perspectives. J Am Coll Cardiol 49 (2007) 1505-1516
28. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137-147
29. Angiolillo D.J., Bernardo E., Sabaté M., et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50 (2007) 1541-1547
30. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 26 (2006) 1895-1900
31. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 115 (2005) 101-108
32. Cuisset T., Frere C., Quilici J., et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4 (2006) 542-549
33. Deray G., Bagnis C., Brouard R., et al. Clopidogrel activities in patients with renal function impairment. Clin Drug Investig 16 (1998) 319-328
34. Hochholzer W., Trenk D., Bestehorn H.P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 (2006) 1742-1750
35. Alfonso F., and Angiolillo D.J. Platelet function assessment to predict outcomes after coronary interventions: hype or hope?. J Am Coll Cardiol 48 (2006) 1751-1754
36. Sibbing D., Braun S., Morath T., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53 (2009) 849-856
37. Salvati F., and Liani M. Role of platelet surface receptor abnormalities in the bleeding and thrombotic diathesis of uremic patients on hemodialysis and peritoneal dialysis. Int J Artif Organs 24 (2001) 131-135
38. Gawaz M.P., Dobos G., Spath M., Schollmeyer P., Gurland H.J., and Mujais S.K. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 5 (1994) 36-46
39. Sloand J.A., and Sloand E.M. Studies on platelet membrane glycoproteins and platelet function during hemodialysis. J Am Soc Nephrol 8 (1997) 799-803
40. Sreedhara R., Itagaki I., and Hakim R.M. Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Am J Kidney Dis 27 (1996) 355-364
41. Geisler T., Grass D., Bigalke B., Stellos K., et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 6 (2008) 54-61
42. Angiolillo D.J., Bhatt D.L., Gurbel P.A., and Jennings L.K. Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol 103 Suppl (2009) 40A-51A
43. Sadeghi H.M., Stone G.W., Grines C.L., et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 108 (2003) 2769-2775
44. Mathis A.S., and Gugger J.J. Percutaneous coronary intervention-related bleeding risk factors in current practice. Ann Pharmacother 39 (2005) 1627-1633
45. Attallah N., Yassine L., Fisher K., and Yee J. Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention. Clin Nephrol 64 (2005) 412-418
46. Berger P.B., Best P.J., Topol E.J., et al. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. Am Heart J 149 (2005) 869-875
47. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
48. Wiviott S.D., Braunwald E., Angiolillo D.J., et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 118 (2008) 1626-1636
49. Ang L., Palakodeti V., Khalid A., et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 52 (2008) 1052-1059